The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?
Executive Summary
Looking ahead at FDA's review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses
You may also be interested in...
FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
A broad label for Cephalon's Treanda could increase the sales potential for the chronic lymphocytic leukemia therapy, which can be used across multiple lines of treatment and as monotherapy or in combination regimens
FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
A broad label for Cephalon's Treanda could increase the sales potential for the chronic lymphocytic leukemia therapy, which can be used across multiple lines of treatment and as monotherapy or in combination regimens
With Promise Of Post-Market Safety Studies, Panel Backs Amgen’s Nplate
FDA's new authority to require post-market studies under the FDA Amendments Act could be the ticket to approval for Amgen's platelet producer Nplate (romiplostim)